OMBCL Unplugged: When The Words “Chronic” & “Cured” Aren’t So Simple
Welcome to our first "Our MBC Life Unplugged" episode, where we wrap up the fall season with an honest, unscripted conversation. What happens when someone is told they might actually be cured? It’s what we all dream of hearing, but when we started talking, it opened a Pandora’s box of questions and concerns:
Is a cure really possible?
Should I go off treatment?
What if the doctor is wrong and my cancer comes back?
This episode dives deep into these complexities and more. So, grab your favorite beverage and join us for a raw, heartfelt discussion you won’t want to miss.
The Project to End Post Partum Breast Cancer
Many people are unfamiliar with Postpartum Breast Cancer (PPBC), a little-known subset of breast cancer that occurs in women within 10 years of childbirth. This episode of our podcast delves into this personal topic for several members of our team.
Drs. Virginia Borges and Pepper Schedin are launching the first-ever clinical trial to prevent PPBC. Their groundbreaking approach involves giving healthy new mothers a brief course of ibuprofen as they wean their babies from breastfeeding. This trial holds huge potential for global impact, and the doctors need the public’s help to make it happen.
MBC 101: Tumor Microenvironment with Dr. Amy Beumer
Have you ever wondered how our cancer metastasizes? Why is it that some treatments just don’t work? Can we as patients living with MBC alter cellular level activity? In this episode, you will hear the answers to these questions and more. Join us as we take a step back to the basics of tumor microenvironment with our guest, Dr. Amy Beumer, who will break down the science into smaller, digestible bites. In this lively discussion, Dr. Amy explains the how and the why of this tough topic. You will hear her say “This is fun” and use engaging, relatable metaphors like “Picture your neighborhood and that one neighbor…..” By the end, I assure you that you’ll walk away with a deeper understanding of tumor microenvironment than when you started.
Pull up a chair, listen in your car, or on your daily walk, we are with you wherever you listen to your podcasts. Terms and other resources are provided in the episode notes.
Protecting Our Loved Ones at Risk
Many with metastatic breast cancer fear for their children and siblings: How can we help them avoid the same diagnosis? Are there ways to minimize risk?
In this episode, host Martha Carlson speaks with her eldest child, who’s navigating personal and family risk factors despite no known genetic predispositions. Join us for this powerful and informative episode where we interview Dr. Sagar Sardesai from Ohio State University’s High Risk Breast Clinic.
Biosimilars and Their Use in Cancer Treatment
On today's episode, we are thrilled to discuss an important and often misunderstood area of oncology- biosimilars and their increasing use in cancer care. You might be curious, what exactly are biosimilars? How are they developed and approved? And most importantly, how are they transforming the lives of patients diagnosed with cancer? We will break down these questions and more as we explore this with an overview from Dr. Julie Gralow, a breast medical oncologist and chief medical officer at the American Society of Clinical Oncology.
Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic treatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.
Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.
Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
We are thrilled to present an audio version of SHARE Cancer Support’s webinar “Report Back from ASCO 2024: Latest Updates on HR+ Metastatic Breast Cancer (MBC)”.
This episode is an in-depth report from the ASCO 2024 Annual Meeting, featuring the latest advancements and research in HR+ MBC. Hear from Dr. Kevin Kalinsky as we dive into the findings from the DESTINY-Breast06 and postMONARCH trials, exploring their implications and potential impact on treatment strategies.
MBC Matters: Understanding Blood Test Results
Blood tests are an essential part of our cancer care. However, interpreting them can often feel like deciphering a foreign language.
Joining us today is Dr. Alfredo Torres and we’ll break down the common types of blood tests, explain what the numbers mean, and discuss how these results impact your treatment plan.
Balancing a Healthy Lifestyle with Eating Chocolate Cake: A Conversation with Dr. Iyengar
There’s a lot of research about how diet and exercise can have a positive effect on survivorship for those with early-stage breast cancer, but about for those of us with MBC? In this episode, we are delighted to bring you a conversation with Dr. Neil Iyengar, a prominent oncologist and researcher known for his deep interest in how lifestyle affects a variety of outcomes. Emerging research and patient experiences are showing that exercise and diet can play a vital role in improving quality of life and may even enhance treatment outcomes. We discuss the science behind diet and exercise along with strategies for balancing lifestyle changes while prioritizing what matters most to us. Whether you’re a patient, a caregiver, or a healthcare professional, this episode is packed with valuable information and insights!
Your Guide to Bone Mets: Exercise (Yes, Exercise!)
In the third of our special series on living with bone metastases, we are turning to one of the most frequent questions and concerns we hear: Can I exercise??
To get the answers, OMBCL co-hosts Ashley Fernandez & Martha Carlson spoke with Dr. Kathryn Schmitz, who has led the way in understanding and implementing exercise for people with breast cancer, including those of us with metastatic breast cancer. Dr. Schmitz founded the Moving Through Cancer initiative of the American College of Sports Medicine, which has a bold goal of making exercise standard of care in oncology by 2029. She fills us in on the science of exercise – why it’s important and how it can be done with bone metastases. Interspersed into the interview with Dr. Schmitz are the stories of people living with bone metastases, providing hope and inspiration that exercise is possible. Be sure to listen to the full episode to get all the suggestions from Dr. Schmitz and hit “Read More” below to go to our episode notes, which link to free videos and other resources.
Your Guide to Bone Mets: Traditional & Innovative Approaches Using Radiation
If you have been diagnosed with MBC bone metastases like the 3 hosts in this episode, this information is for you! Bone Mets are extremely common in MBC. In the first half of the episode, we explain the field of radiation oncology and all it covers, with Dr Kalnicki from Montefiore Einstein Comprehensive Cancer Center in Bronx, NY; in the second half we feature an interview with the leader of the Duke Center for Brain and Spine Metastasis. Duke’s approach to managing bone mets includes a comprehensive team of specialists that offer the traditional and some less commonly seen treatments, like Cryoablation (freezing) and Radiofrequency Ablation (heating) of tumors. We also cover emerging science in bone mets, like “Theranostics” which is having success in prostate cancers and may hold promise for MBC. So listen here and learn with us, and check out our show notes for the links to what’s covered in the episode.
Your Guide to Bone Mets: The Basics
Today’s episode is the first in a three part series covering all things related to bone metastasis. In this episode, we discuss the basics with Dr. Azeez Farooki and Dr. Monica Fornier, both specialists in their fields at MSK, diving into the latest breakthroughs in bone disease and breast cancer research. Topics include theories on why breast cancer spreads to the bones, as well as new drug protocols shaping the future of bone metastasis research and treatment. We unlock the wisdom of these top experts as they bridge the gaps between advancing research and patient care in a thought provoking conversation.
OMBCL Shorts #2: Dr. Erika Hamilton with Top Takeaways from ASCO23
Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23. In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
OMBCL Shorts #1: Dr. Stephanie Graff & Her Steps For Those Newly Diagnosed MBC
Our inaugural OMBCL Shorts features Dr. Stephanie Graff talking about what she does when someone is newly diagnosed with MBC. This season, we had a 3-part series for people newly diagnosed and we couldn't resist getting her take on the topic. And we're so glad we asked!
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
Newly Diagnosed with MBC: Tests, Terms, & Tips with Dr. Rebecca Shatsky
Being diagnosed with MBC can feel like you’ve been dropped into a dangerous and alien landscape, one whose inhabitants speak a new and confusing language. Numb and bewildered, you face a mountain of medical decisions—each with seemingly high stakes. The last in Our MBC Life’s 3-part series for people newly diagnosed with MBC, this episode's interview with Dr. Rebecca Shatsky, interspersed with experienced-patient voices, sheds light on cancer types, tests, and treatment—and empowers listeners to navigate this challenging new terrain with understanding, knowledge, and confidence.
Newly Diagnosed & Trailblazing: An Interview with Michelle Anderson-Benjamin
In this episode, Our MBC Life sits down with patient and advocate Michelle Anderson-Benjamin, founder of The Fearless Warrior Project. During the pandemic, Michelle was diagnosed with early-stage breast cancer and then with metastatic breast cancer shortly after she completed initial treatment. An experienced healthcare professional, a mom of two kids, and a wife who poured all her energy into others, Michelle says the diagnosis of MBC put a "battery in her back" to refocus attention on herself. This candid conversation has a lot to offer those newly diagnosed with MBC, and will inspire all of us.
Newly Diagnosed with MBC: Keeping Your Balance on the Emotional Rollercoaster
Hearing the words “you have metastatic breast cancer” is devastating. Whether your diagnosis comes de novo or months, years, or even decades after treatment for early-stage breast cancer, there is no way to prepare for the terror, anger, despair, and sense of freefall that follows. You’ll hear from oncology social worker Lisa Nelson and a candid group of patients on the challenges of processing the diagnosis.
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.